Publication:
Psoriasis and the liver: problems, causes and course

Simple item page
dc.contributor.authorSEÇKİN GENÇOSMANOĞLU, DİLEK
dc.contributor.authorsTula, Elona; Ergun, Tulin; Seckin, Dilek; Ozgen, Zuleyha; Avsar, Erol
dc.date.accessioned2022-03-12T20:31:52Z
dc.date.available2022-03-12T20:31:52Z
dc.date.issued2017
dc.description.abstractBackground/ObjectivesPsoriasis patients have a higher risk of liver abnormalities such as non-alcoholic fatty liver disease (NAFLD), drug-induced hepatitis, alcoholic hepatitis and neutrophilic cholangitis, than the general population. Associated liver disease limits therapeutic options and necessitates careful monitoring. The aim of the study was to identify liver problems in psoriasis patients and to investigate the underlying causes as well as their course. MethodsThe files of 518 psoriasis patients were retrospectively reviewed. Among these, 393 patients with relevant laboratory data were analysed for liver enzymes and their relation to the known risk factors for liver disease (obesity, diabetes mellitus, alcohol consumption, hepatotoxic medications, dyslipidemia, psoriatic arthritis and infectious hepatitis). ResultsAmong 393 patients, 24% and 0.8% developed liver enzyme abnormalities and cirrhosis, respectively. The most common factors associated with pathological liver enzymes were drugs (57%) and NAFLD (22%). Other rare causes were alcoholic hepatitis, viral hepatitis, neutrophilic cholangitis, autoimmune hepatitis and toxic hepatitis due to herbal therapy. Drug-induced liver enzyme abnormalities were reversible whereas in patients with NAFLD transaminases tended to fluctuate. One patient with herbal medicine-related cirrhosis died of sepsis. ConclusionLiver enzyme abnormalities are common in psoriasis patients and are mostly associated with drugs and NAFLD. Although most cases can be managed by avoiding hepatotoxic medications and close follow up, severe consequences like cirrhosis may develop.
dc.identifier.doi10.1111/ajd.12460
dc.identifier.eissn1440-0960
dc.identifier.issn0004-8380
dc.identifier.pubmed26916498
dc.identifier.urihttps://hdl.handle.net/11424/234336
dc.identifier.wosWOS:000408643500038
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofAUSTRALASIAN JOURNAL OF DERMATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectdrug-induced hepatitis
dc.subjecthepatotoxicity
dc.subjectnon-alcoholic fatty liver
dc.subjectpsoriasis
dc.subjectGENERALIZED PUSTULAR PSORIASIS
dc.subjectMONITORING PATIENTS
dc.subjectACUTE HEPATITIS
dc.subjectSKIN-DISEASE
dc.subjectLONG-TERM
dc.subjectMETHOTREXATE
dc.subjectFIBROSIS
dc.subjectMANAGEMENT
dc.subjectARTHRITIS
dc.subjectPROCOLLAGEN
dc.titlePsoriasis and the liver: problems, causes and course
dc.typearticle
dspace.entity.typePublication
local.avesis.iddbf20a0e-5ae3-429d-a86e-db9f1db81511
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages6
local.journal.quartileQ3
oaire.citation.endPage199
oaire.citation.issue3
oaire.citation.startPage194
oaire.citation.titleAUSTRALASIAN JOURNAL OF DERMATOLOGY
oaire.citation.volume58
relation.isAuthorOfPublicationacf48150-1ebd-4a7f-8b28-8d8f349ebeed
relation.isAuthorOfPublication.latestForDiscoveryacf48150-1ebd-4a7f-8b28-8d8f349ebeed

Files

Collections

Research Outputs